Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

BACKGROUND: A therapeutic strategy involving combined treatment with lenvatinib plus pembrolizumab (LEP) has demonstrated a relatively high antitumor response in several solid tumors; however, the efficacy and safety of LEP in patients with refractory bile tract carcinoma (BTC) remains unknown. METH...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Hepatobiliary Surg Nutr
Główni autorzy: Lin, Jianzhen, Yang, Xu, Long, Junyu, Zhao, Songhui, Mao, Jinzhu, Wang, Dongxu, Bai, Yi, Bian, Jin, Zhang, Lei, Yang, Xiaobo, Wang, Anqiang, Xie, Fucun, Shi, Weiwei, Yang, Huayu, Pan, Jie, Hu, Ke, Guan, Mei, Zhao, Lin, Huo, Li, Mao, Yilei, Sang, Xinting, Wang, Kai, Zhao, Haitao
Format: Artigo
Język:Inglês
Wydane: AME Publishing Company 2020
Hasła przedmiotowe:
Original Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7423565/
https://ncbi.nlm.nih.gov/pubmed/32832493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/hbsn-20-338
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy